GLRA2

GLRA2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GLRA2</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GLRA2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Glycine Receptor Alpha 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xp22.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2745</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>305990</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P23416</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000145888</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>462 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~52 kDa</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GLRB</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">Gephyrin</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Collybistin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">Raphenin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">GABARAP</td>
<td>Cargo receptor</td>
</tr>
<tr>
<td class="label">Syntaxin-1A</td>
<td>SNARE</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">GLRA1</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRA3</td>

GLRA2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GLRA2</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GLRA2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Glycine Receptor Alpha 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xp22.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2745</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>305990</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P23416</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000145888</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>462 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~52 kDa</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GLRB</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">Gephyrin</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Collybistin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">Raphenin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">GABARAP</td>
<td>Cargo receptor</td>
</tr>
<tr>
<td class="label">Syntaxin-1A</td>
<td>SNARE</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">GLRA1</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRA3</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRA4</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRB</td>
<td>Partner</td>
</tr>
<tr>
<td class="label">GLRA1P</td>
<td>Pseudogene</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

GLRA2 (Glycine Receptor Alpha 2) encodes the alpha-2 subunit of the glycine receptor (GlyR), a ligand-gated chloride channel that mediates inhibitory neurotransmission in the central nervous system. Glycine receptors are crucial for motor control, sensory processing, respiratory function, and pain modulation[@lynch2004]. The GLRA2 gene is located on the X chromosome (Xp22.2) and is primarily expressed during embryonic and early postnatal development, with expression decreasing in adulthood[@sato2018].

Mutations in GLRA2 are associated with hyperekplexia (startle disease), a neurological disorder characterized by an exaggerated startle response to unexpected stimuli. Additionally, GLRA2 variants have been implicated in epileptic encephalopathy and various neurodevelopmental disorders[@harvey2009][@chung2010]. The alpha-2 subunit has distinct pharmacological properties compared to other glycine receptor subunits, making it an interesting target for drug development[@grudzinska2005].

Gene and Protein Structure

Genomic Organization

Protein Domain Structure

The glycine receptor alpha-2 subunit contains several functional domains:

Biological Functions

Glycine Receptor Structure and Assembly

Glycine receptors are pentameric ligand-gated chloride channels typically composed of alpha and beta subunits[@legendre2001]:

• Alpha subunits: Four isoforms (GLRA1, GLRA2, GLRA3, GLRA4) form the ligand-binding interface
• Beta subunit (GLRB): Provides structural stability and targets receptors to the synapse
• Stoichiometry: Usually 2 alpha subunits + 3 beta subunits (α2β)
• Assembly: Alpha-2 subunits can form homomeric receptors or heteromeric assemblies with other alpha isoforms

GlyR Alpha-2 Specific Properties

The alpha-2 subunit has distinctive functional properties[@grudzinska2005]:

Inhibitory Neurotransmission

Glycine receptor-mediated inhibition is essential for:

• Motor control: Modulation of motor neuron activity and reflex arcs
• Respiratory regulation: Central chemoreception and respiratory rhythm generation
• Pain modulation: Spinal cord pain transmission gating
• Startle response: Mediates the acoustic startle reflex
• Sensorimotor integration: Coordinates sensory processing with motor output

Chloride Channel Function

When glycine binds to the receptor:

Molecular Mechanisms

Ligand Binding and Channel Gating

The glycine binding site is located at the interface between adjacent alpha subunits[@betz1998]:

Signal Transduction Pathway

Protein Interactions

GLRA2 interacts with several proteins for proper function and localization:

Disease Associations

Hyperekplexia (Startle Disease)

Hyperekplexia is a neurological disorder characterized by an exaggerated startle response to unexpected auditory, visual, or tactile stimuli[@becker2008]. GLRA2 mutations account for a significant portion of X-linked hyperekplexia cases[@chung2010]:

Clinical Features:

• Hypertonia in infancy, particularly in response to sudden stimuli
• Exaggerated startle response
• Apnea episodes and occasional sudden infant death
• Persistent startle into adulthood
• Falls without loss of consciousness (atonic seizures)

• Inheritance: X-linked recessive (GLRA2) or autosomal dominant (GLRA1)
• Mutations: Missense, nonsense, and splice-site mutations
• Mechanism: Loss of receptor function or impaired trafficking

• Reduced glycine receptor function leads to hyperexcitability
• Impaired inhibitory neurotransmission in brainstem and spinal cord
• Enhanced startle reflex due to disinhibition of motor circuits

• Clonazepam: Primary treatment, enhances GABAergic inhibition
• Valproic acid: Anticonvulsant properties
• L-tryptophan: Precursor to serotonin, may reduce startle

Epileptic Encephalopathy

GLRA2 variants have been associated with epileptic encephalopathy[@diaz2013][@rudolf2019]:

Alzheimer's Disease

Changes in glycine receptor expression and function have been reported in Alzheimer's disease[@baker2015]:

• Downregulation: GLRA2 expression decreased in AD brain
• Synaptic dysfunction: Loss of glycinergic inhibition contributes to network hyperexcitability
• Calcium dysregulation: Altered glycine receptor signaling affects calcium homeostasis

Parkinson's Disease

Glycinergic dysfunction is implicated in Parkinson's disease motor complications:

• Basal ganglia alterations: Changes in glycine receptor expression
• Spasticity: Enhanced glycinergic inhibition may contribute to rigidity
• Therapeutic implications: Glycinergic agents as potential adjunct therapy

Expression Patterns

Developmental Regulation

GLRA2 shows stage-specific expression[@sato2018]:

• Embryonic: High expression in developing spinal cord and brainstem
• Postnatal: Peak expression in first weeks after birth
• Adult: Expression decreases, alpha-1 becomes dominant

Brain Regions

High expression in:

• Spinal cord: Substantia gelatinosa (lamina II), motor horn
• Brainstem: Reticular formation, cranial nerve nuclei
• Hippocampus: CA1 region, dentate gyrus
• Cerebellum: Deep nuclei, Purkinje cell layer

Cellular Localization

• Postsynaptic membranes: Concentrated at inhibitory synapses
• Somatodendritic: Primarily on cell bodies and dendrites
• Axon initial segments: Where action potentials are initiated

Therapeutic Implications

Current Treatment Strategies

For hyperekplexia and related disorders[@mollard2022]:

Drug Development

Targeting GLRA2 for therapeutic benefit:

Challenges

• Blood-brain barrier limits drug delivery
• Developmental regulation complicates timing
• Heterogeneous mutations require personalized approaches
• Need for early intervention before irreversible damage

Animal Models

Mouse Models

• Glra2 knockout mice: Show increased startle response
• Transgenic models: Express mutant human GLRA2
• Phenotypes: Hyperactive startle, motor deficits

Zebrafish Models

• Morpholino knockdown studies
• Startle response assays
• Drug screening platforms

Interaction Network

Related Genes

Signaling Pathways

• Gephyrin pathway: Synaptic clustering and stabilization
• Collybistin pathway: Membrane targeting
• Phosphorylation pathway: Modulation of receptor function

Cross-Links

• [Related Genes*: [GLRA1](/genes/glra1), [GLRA3](/genes/glra3), [GLRB](/genes/glrb), [GLRA4](/genes/glra4)](/genes)
• [Related Proteins*: [Glycine Receptor](/entities/glycine-receptors), [Gephyrin](/entities/gephyrin)](/proteins)
• [Related Mechanisms*: [Inhibitory Neurotransmission](/mechanisms/inhibitory-neurotransmission), [Chloride Channels](/mechanisms/chloride-channels)](/mechanisms)
• [Related Diseases: [Hyperekplexia](/diseases/hyperekplexia), [Epilepsy](/diseases/epilepsy), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease)
• [Brain Regions: [Spinal Cord](/brain-regions/spinal-cord), [Brainstem](/brain-regions/brainstem), [Hippocampus](/brain-regions/hippocampus)](/brain-regions)

References